Meta Biomed Co. Ltd (059210) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Meta Biomed Co. Ltd (059210) has a cash flow conversion efficiency ratio of 0.009x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩1.05 Billion ≈ $714.42K USD) by net assets (₩121.24 Billion ≈ $82.16 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Meta Biomed Co. Ltd - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how Meta Biomed Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read 059210 current and long-term liabilities for a breakdown of total debt and financial obligations.
Meta Biomed Co. Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Meta Biomed Co. Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Suprema HQ Inc
KQ:094840
|
-0.006x |
|
Genie Music Corporation
KQ:043610
|
-0.005x |
|
Universal Inc
TW:1325
|
0.006x |
|
Drb Holding
KO:004840
|
0.042x |
|
Grupo Mexicano de Desarrollo S.A.B
MX:GMD
|
0.017x |
|
Campina Ice Cream Industry Tbk PT
JK:CAMP
|
0.086x |
|
Genesem Inc
KQ:217190
|
-0.007x |
|
Prolific Technology
TWO:6233
|
-0.006x |
Annual Cash Flow Conversion Efficiency for Meta Biomed Co. Ltd (2011–2024)
The table below shows the annual cash flow conversion efficiency of Meta Biomed Co. Ltd from 2011 to 2024. For the full company profile with market capitalisation and key ratios, see Meta Biomed Co. Ltd stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩93.34 Billion ≈ $63.25 Million |
₩22.63 Billion ≈ $15.34 Million |
0.242x | +72.44% |
| 2023-12-31 | ₩72.66 Billion ≈ $49.24 Million |
₩10.22 Billion ≈ $6.92 Million |
0.141x | -6.98% |
| 2022-12-31 | ₩60.59 Billion ≈ $41.06 Million |
₩9.16 Billion ≈ $6.21 Million |
0.151x | -20.83% |
| 2021-12-31 | ₩58.32 Billion ≈ $39.52 Million |
₩11.14 Billion ≈ $7.55 Million |
0.191x | +88.43% |
| 2020-12-31 | ₩47.98 Billion ≈ $32.51 Million |
₩4.86 Billion ≈ $3.29 Million |
0.101x | +88.40% |
| 2019-12-31 | ₩53.27 Billion ≈ $36.10 Million |
₩2.86 Billion ≈ $1.94 Million |
0.054x | +150.87% |
| 2018-12-31 | ₩49.97 Billion ≈ $33.86 Million |
₩-5.28 Billion ≈ $-3.58 Million |
-0.106x | -1857.36% |
| 2017-12-31 | ₩46.01 Billion ≈ $31.18 Million |
₩-248.51 Million ≈ $-168.41K |
-0.005x | -105.54% |
| 2016-12-31 | ₩51.59 Billion ≈ $34.96 Million |
₩5.03 Billion ≈ $3.41 Million |
0.098x | +0.59% |
| 2015-12-31 | ₩50.87 Billion ≈ $34.47 Million |
₩4.93 Billion ≈ $3.34 Million |
0.097x | +1547.11% |
| 2014-12-31 | ₩44.20 Billion ≈ $29.96 Million |
₩-296.24 Million ≈ $-200.76K |
-0.007x | -108.04% |
| 2013-12-31 | ₩44.54 Billion ≈ $30.18 Million |
₩3.71 Billion ≈ $2.52 Million |
0.083x | -11.04% |
| 2012-12-31 | ₩40.89 Billion ≈ $27.71 Million |
₩3.83 Billion ≈ $2.60 Million |
0.094x | -10.84% |
| 2011-12-31 | ₩39.05 Billion ≈ $26.46 Million |
₩4.10 Billion ≈ $2.78 Million |
0.105x | -- |
About Meta Biomed Co. Ltd
Meta Biomed Co., Ltd. engages in the research and development, production, and marketing of dental and surgical materials in South Korea and internationally. The company's dental products include endodontics, endodontic materials, restorative materials, and bone graft materials. It also offers suture products comprising multifilament and monofilament products, as well as orthopedics; bone product… Read more